Changes of plasma cytokines content in Graves’ orbitopathy patients, could be potential markers

Abstract

Aims: The purpose of this study was to detect potential cytokines markers involved in the Graves’ orbitopathy (GO). Materials and Methods: We measured 25 plasma cytokines using label-free quantitative proteomic analysis in the pilot cohort. In validation cohort, NORCH3, TBP, α-enolase (ENO1), GPX3, ORM1, extracellular matrix protein-1 (ECM1), SERPINE, IGF1, IGKV1, and SPARC were validated using ELISA kits. We used label-free liquid chromatography–mass spectrometry/MS (LC–MS/MS) quantitative proteomic to analyze plasma cytokines content of Graves’ disease and GO patients. Results: The validation cohort showed that the concentrations of ECM1, ENO1, and GPX3, (244.4276 pg/ml, 4.361807 ng/ml, and 17.72794 pmol/ml, respectively) were significantly lower in GO patients samples than those in Graves’ patients (257.3197 pg/ml, 4.601592 ng/ml, and 21.33118 pmol/ml, respectively). Both univariate and multivariate logistic analyses indicated that GPX3, ECM1, and ENO might be predictors of Graves’ ophthalmopathy. A receiver-operating characteristic curve with an area under the curve of 0.938, a sensitivity of 84.4%, and a specificity of 90.5% underscored the applicability of this method. Conclusions: ECM1, ENO1, and GPX3 were associated with the presence of the GO group and may be good biomarkers that play an important role in the pathogenesis of GO.

Keywords

• graves’ orbitopathy
• label-free liquid chromatography–mass spectrometry/mass spectrometry
• plasma protein
• potential markers